Risultati per: È confermato il legame tra la malattia di Alzheimer e microbiota intestinale

Tecnologia dell’Università Carlo Bo esplora uso di globuli rossi

The US Food and Drug Administration (FDA) recently approved donanemab, a monoclonal antibody to treat Alzheimer disease in its early stages. Marketed by Eli Lilly as Kisunla, the drug is the second to receive the FDA’s go-ahead for slowing Alzheimer disease, after lecanemab. Like lecanemab, donanemab is designed to clear amyloid plaque in people with mild cognitive impairment or mild dementia.

Objective
Probiotic Lactococcus lactis is known to confer health benefits to humans. Here, we aimed to investigate the role of L. lactis in colorectal cancer (CRC).

Design
L. lactis abundance was evaluated in patients with CRC (n=489) and healthy individuals (n=536). L. lactis was isolated from healthy human stools with verification by whole genome sequencing. The effect of L. lactis on CRC tumourigenesis was assessed in transgenic Apc Min/+ mice and carcinogen-induced CRC mice. Faecal microbiota was profiled by metagenomic sequencing. Candidate proteins were characterised by nano liquid chromatography-mass spectrometry. Biological function of L. lactis conditioned medium (HkyuLL 10-CM) and functional protein was studied in human CRC cells, patient-derived organoids and xenograft mice.

Results
Faecal L. lactis was depleted in patients with CRC. A new L. lactis strain was isolated from human stools and nomenclated as HkyuLL 10. HkyuLL 10 supplementation suppressed CRC tumourigenesis in Apc Min/+ mice, and this tumour-suppressing effect was confirmed in mice with carcinogen-induced CRC. Microbiota profiling revealed probiotic enrichment including Lactobacillus johnsonii in HkyuLL 10-treated mice. HkyuLL 10-CM significantly abrogated the growth of human CRC cells and patient-derived organoids. Such protective effect was attributed to HkyuLL 10-secreted proteins, and we identified that α-mannosidase was the functional protein. The antitumourigenic effect of α-mannosidase was demonstrated in human CRC cells and organoids, and its supplementation significantly reduced tumour growth in xenograft mice.

Conclusion
HkyuLL 10 suppresses CRC tumourigenesis in mice through restoring gut microbiota and secreting functional protein α-mannosidase. HkyuLL 10 administration may serve as a prophylactic measure against CRC.

This cohort study investigates the association of changes in levels of plasma tau phosphorylated at threonine 181 and neurofilament light chain protein with psychotic symptoms in Alzheimer disease.

Un nuovo studio suggerisce che il primo farmaco Glp-1 impiegato per combattere diabete e obesità, può ridurre la perdita di massa cerebrale

Lo conferma uno studio su 1.200 persone

This Medical News article is an interview with retired neurologist Daniel Gibbs, who is living with Alzheimer disease.

In Lombardia uno studio pilota promosso da Telethon coinvolgerà 100mila neonati. Obiettivo: validare il test per la diagnosi di leucodistrofia metacromatica

Almost all people who inherited 2 identical copies of the APOE4 gene variant had abnormally high levels of amyloid in their cerebrospinal fluid and brain by age 65 years, according to a new study that combined data from more than 3200 brain donors and about 10 000 participants with clinical data.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Volume 390, Issue 23, Page 2217-2219, June 20, 2024.

New England Journal of Medicine, Volume 390, Issue 23, Page 2156-2164, June 20, 2024.

New England Journal of Medicine, Volume 390, Issue 23, Page 2212-2213, June 20, 2024.

This Viewpoint discusses how data gaps in published research impede clinicians’ ability to clearly discuss the risks and benefits of amyloid-lowering drugs for treating Alzheimer disease.

I consulenti dell’Fda hanno approvato il farmaco di Eli Lilly. Entro la fine dell’anno si attende l’ok definitivo da parte dell’Ente regolatorio